BRCA1-Delta11q is significantly associated with breast cancer resistance to PARPi and cisplatin and patient survival, although inhibition of its splicing can improve sensitivity to PARPi (40); therefore, it has value as a therapeutic target. This evidence concerns the gene BRCA1 and breast carcinoma.